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Abstract
Polycystic ovarian syndrome (PCOS) is a common, heterogeneous, complex, endocrino-
pathic condition that causes menstrual dysfunction and infertility in women. Traditional 
Chinese medicine (TCM) has been widely used for PCOS in Far-East countries for thou-
sands of years. There are significant advantages in treating PCOS with TCM. This chapter 
aims to investigate the current developments in TCM therapy for PCOS.
Keywords: complementary and alternative therapy, traditional Chinese medicine, 
polycystic ovarian syndrome, acupuncture, moxibustion
1. Introduction
1.1. Definition
Polycystic ovarian syndrome (PCOS) is characterized by endocrine and ovarian disorders 
that affect quality of life in women of reproductive age. In 1935, PCOS was first described by 
Stein and Leventhal with a description of seven women suffering from amenorrhea, hirsut-
ism, and enlarged ovaries with multiple cysts [1, 2]. Some different criteria about the National 
Institute of Health (NIH), Rotterdam criteria, Androgen Excess Society and Polycystic Ovary 
Syndrome Society guidelines (AE-PCOS) are shown in Table 1 [3–8].
1.2. Epidemiology
Globally, PCOS affects 5–20% of women of reproductive age [9]. One report summarized the 
incidence of PCOS as 6–13% in Hispanic women, 3–9% in African American women, and 2–9% 
in Asian women [10]. The prevalence of PCOS in different geographical regions ranges from 
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5 to 10% according to the NIH 1990 criteria, from 10 to 15% according to the AE-PCOS 2006 
criteria, and from 6 to 21% when the Rotterdam criteria are applied [7]. East Asian subjects 
(Korean, Chinese, and Thai) appear to have a lower prevalence of PCOS (about 5%) compared 
to Caucasian women (11–20%) [11].
One systematic review and meta-analysis showed the incidence of PCOS phenotypes using 
the 2012 NIH criteria was 50% for phenotype A, 13% for phenotype B, 14% for phenotype C, 
and 17% for phenotype D [12].
1.3. Comorbidities
Patients with PCOS often have comorbidities such as obesity, insulin resistance/type II diabe-
tes mellitus (Type II DM), dyslipidemia, hypertension/cardiovascular disease, infertility/sub-
fertility, or cancer. One systematic review and meta-analysis demonstrated that women with 
PCOS had a pooled prevalence of 61% for overweight [body mass index (BMI) > 25], 49% for 
obesity (BMI > 30), and 54% for central obesity [13]. Insulin resistance (IR) is present in 50–80% 
of these women, which is associated with obesity [14, 15]. Both lean (30%) and obese women 
(70%) with PCOS show decreased insulin sensitivity [16].
Title NIH 1992 Rotterdam 2003 AE-PCOS 2006 NIH 2012 extension of Rotterdam 
2003
Criteria • Clinical or 
biochemical 
androgen excess
• Rare ovulations
• Clinical or 
biochemi-
cal androgen 
excess
• Oligo- or 
anovulation
• Polycystic 
ovaries
• Clinical or 
biochemi-
cal androgen 
excess
• Ovarian dys-
function and/
or polycystic 
ovaries
• Clinical or biochemical andro-
gen excess
• Oligo- or anovulation
• Polycystic ovaries
Restriction Need both criteria Need two of three 
criteria
Need both criteria • Need two of three criteria
• Specifically identifying the four 
sub-phenotype:
A. Androgen Excess + Ovula-
tory Dyfunction + Polycystic 
Ovaries
B. Androgen Excess + Ovulatory 
Dysfunction
C. Androgen Excess + Polycystic 
Ovaries
D. Ovulatory Dysfunction + Pol-
ycystic Ovarian Morphology
Exclusion Exclusion of other androgen excess and other similar etiology
Table 1. Diagnostic criteria for PCOS.
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Around 27% of premenopausal women with PCOS have type II DM [17]. Dyslipidemia may 
be up to 70% in women with PCOS [18, 19]. In a large study of European and American 
women with PCOS, the total cholesterol and low-density lipoprotein cholesterol (LDL-C) lev-
els increased significantly, up to 29 and 16 mg/dl, respectively, in non-Hispanic white, obese 
women with PCOS compared to obese women without PCOS [19]. This study also noted that 
the total cholesterol and LDL-C levels were elevated significantly, up to 32 and 32 mg/dl, 
respectively, in nonobese women with PCOS compared to nonobese women without PCOS 
[19]. Another worldwide systematic review and meta-analysis demonstrated that triglycer-
ides (TG) and LDL-C levels were 26 and 12 mg/dl higher, and high-density lipoprotein cho-
lesterol (HDL-cholesterol) concentration was 6 mg/dl lower than that of controls [20].
One clinical study demonstrated that nearly 26% of women with PCOS have hypertension 
[21]. The metabolic imbalances in patients with PCOS cause chronic low-grade inflammation 
and cardiovascular disturbances, which increase the risk of cardiovascular disease [22]. One 
systematic review and meta-analysis showed a 2-fold increased risk of coronary heart disease 
(CHD) and stroke for women with PCOS compared to those without PCOS [23].
Women with PCOS account for around 80% of women with anovulatory infertility [24, 25]. 
A recently systematic review and meta-analysis showed that women of all ages with PCOS 
were at a significantly increased risk [odds ratio (OR) up to 2.79] for endometrial cancer [26]. 
Moreover, this study also revealed that when women over 54 years of age were excluded from 
the analysis, the risk for women with PCOS increased more (OR up to 4.05) for endometrial 
cancer and for ovarian cancer (OR up to 2.52), but stable for breast cancer [26].
2. Etiology
The etiology of PCOS is still not clear. A systematic review suggested that post-natal expo-
sure to androgens results in reprogramming of the hypothalamic-pituitary-ovarian-axis [27]. 
Recently, some clinical studies have confirmed that human fetal androgen excess promotes 
PCOS development after birth by checking infant blood levels at term [28]. The circulating 
androgen levels of the human female fetus in the second trimester can increase into the male 
range and mid-gestational amniotic testosterone levels in female fetuses of PCOS mothers 
may be higher than those in normal mothers, which might influence fetal development [28]. 
Another review article mentioned that the fetal ovary is more likely to produce an excess of 
androgens in response to maternal human chorionic gonadotropin (hCG) in subjects geneti-
cally predisposed to PCOS [29]. Furthermore, some genetic variations are associated with 
PCOS. For example, DENND1A is found in the cytoplasm and nuclei of ovarian theca cells. 
Over expression of DENND1A variant 2 results in a PCOS-like phenotype, and knock-down 
of DENND1A variant 2 in PCOS theca cells reversed this phenotype [30]. In addition, a recent 
review showed that genome-wide association studies (GWAS) have identified some loci con-
taining genes with clear roles in reproductive (LHCGR, FSHR, and FSHB) and metabolic 
(INSR and HMGA2) dysfunction in PCOS [31].
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3. Diagnosis
There are several diagnostic criteria for PCOS such as NIH 1990/2012, ESHRE/ASRM 2003 
(Rotterdam), or AE-PCOS 2006. Diagnosis of PCOS should take into consideration the history, 
clinical manifestations, ultrasound imaging results, and serum examination results.
3.1. History taking
Menstrual abnormality such as oligo-anovulation (OA) is usually noted [32]. According to the 
Rotterdam criteria, OA is defined as less than eight episodes of menses a year or cycle lengths 
of more than 35 days [5]. A stricter definition, such as less than eight menstruations and/or two 
cycles of less than 22 or more than 42 days per year, the prevalence of OA drops to 14% and 
OA becomes highly predictive of PCOS [33, 34]. Although 30% of women with PCOS will have 
normal menses [2, 35], 85–90% of women with OA have PCOS, while 30–40% of women with 
amenorrhea have PCOS [2, 36]. After the age of 40, women with PCOS often have more regular 
menstrual cycles while women over 30 who develop OA are less likely to have PCOS [32].
Weight gain and central obesity are common presentations in PCOS and usually come before 
the onset of anovulatory cycles [14]. In the United States, the prevalence of obesity in girls 
aged 12–19 years in 2007–2008 was 17%, compared with 50–80% among adolescent girls with 
PCOS [13, 37–40].
3.2. Clinical manifestations
Clinical manifestations are acne, hirsutism, and androgenic alopecia . Some patients appear 
with only one or two manifestations, while a few patients have all the three [2]. Sixty percent 
of patients with PCOS have hirsutism and 15–25% patients have acne [6].
3.3. Other diagnostic methods
The BMI, blood pressure, waist circumference (WC), and hip circumference should be mea-
sured at the initial visit. Fasting lipid profile, sugar and glycohemoglobin, or a 2-hour oral 
glucose tolerance test (OGTT) should be performed if PCOS is suspected at the initial visit. 
Trans-vaginal ultrasound is indicated rather than trans-abdominal ultrasound if the patient 
has one of either irregular menstruation or HA. The Rotterdam PCOM criteria, considered to 
have sufficient specificity and sensitivity to define PCOM, requires the presence of ≥12 follicles 
measuring 2–9 mm in diameter and/or increased ovarian volume (>10 cm3) in a single ovary or 
both ovaries [32, 41–42]. In 2014, the AE-PCOS guidelines suggested using follicle number per 
ovary (FNPO) ≥25 for the definition of PCOM when using newer technology that allows maxi-
mal resolution of ovarian follicles (such as a transducer frequency of more than 8 MHz) [41, 43].
Serum hormone examination, such as serum androgens, should be performed on women 
with clinical appearance of PCOS. In addition, anti-Müllerian hormone (AMH) in women is 
generated by granulosa cells, and preantral and antral follicles, and its major function seems 
to be limited to inhibit the development of the initial stage of follicular maturation [44]. Serum 
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AMH in women with PCOS is higher than in healthy women, which probably reflects the 
number of small follicles observed on the ultrasounds of polycystic ovaries [45]. Studies have 
reported that 97% of women with AMH >10 ng/mL had PCOS and this correlated positively 
with LH, total testosterone, and DHEA [45, 46]. Besides, serum AMH revealed high predictive 
ability for the presence of OA or amenorrhea [45, 46]. Recently, serum AMH is proving to be 
a better tool to understand ovarian function and follicular count; however, the clinical use of 
serum assays for AMH still poses some technical problems [33, 44].
4. Conventional management and limitations
Management of PCOS is limited to improve clinical manifestations, since the real etiology of 
the disorder is unclear [47]. While multiple cardiovascular risk factors such as obesity, dys-
lipidemia, hypertension, and DM are prevalent in PCOS, current therapeutic management of 
PCOS usually focuses firstly on the treatment of metabolic disturbances (anovulation, men-
strual irregularity, and hirsutism) and secondly on the control of reproductive hormones or 
insulin levels [48]. Lifestyle modifications including increased exercise, dietary changes, and 
weight loss are appropriate first-line interventions for many women with PCOS [49]. Diet 
therapy for patients with PCOS includes the design of low-calorie diets to achieve weight 
loss or preserve a healthy weight, restrict the intake of simple sugars, and increase the con-
sumption of foods with a low glycemic index and refined carbohydrates, a decrease in the 
consumption of trans and saturated fatty acids, and awareness of possible deficiencies such 
as omega-3, vitamin D, and chromium [50]. One systematic review and meta-analysis dem-
onstrated that moderate physical activity mostly 12 or 24 weeks would improve ovulation, 
decreased IR (9–30%), and weight loss (4.5–10%) [51]. The AE-PCOS guidelines suggested 
a target of caloric, diet, and body weight control in PCOS women with more restrictions if 
dyslipidemia occurred [52–54]. The detailed information is listed in Table 2 [52–54].
Nutrition recommendations Methods
Limitation of calories Decrease current diet 500–1000 kcal/day
Reduction of fat Decrease total fat (less than 30% total caloric intake) and 
saturated fat (less than 10% total caloric intake)
Favor foods intake Increase fiber, vegetables, fruit, cereals, wholegrain breads, 
monounsaturated and polyunsaturated fat intake
Suggestions if dyslipidemia Expect reduction in LDL-C (%)
Reduce body weight by 7–10% 5–8%
Decrease saturated fat to 7% total energy 8–10%
Decrease dietary cholesterol to <200 mg daily 3–5%
Decrease transfat to 1% total energy 2%
Increase 2 g of plant stanols daily 6-–0%
Add 5–10 g viscous fiber daily 3–5%
Table 2. Nutritional recommendations for PCOS women from the AE-PCOS society.
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Unfortunately, lifestyle interventions are associated with low adherence and sustainability, 
and engagement, compliance, and sustainability remain challenging [55]. Medical treatment 
of PCOS is indicated if lifestyle modifications are a failure or unsuitable. Medical treatments 
include clomiphene citrate, metformin, oral contraceptives (OCPs), anti-androgen, steroids, 
and statins. One-year randomized clinical trial (RCT) showed that combined oral contracep-
tives plus spironolactone can decrease hirsutism score, androgens, and DHEA levels with fewer 
menstrual dysfunction [56]. Another randomized, controlled crossover study demonstrated 
that both metformin and myoinositol significantly reduced the insulin response to OGTT and 
Medical agents Indication and effect Limitations
Clomiphene citrate *As an ovary-stimulating drug in subfertile 
/infertile women
*Nonsteroidal synthetic hormone consisting of 
a racemic mixture of two stereoisomers (40% 
enclomiphene [EnC] and 60% zuclomiphene  
[ZuC]), with anti-estrogenic properties
*Possible fetal malformations, mainly 
neural tube defects and hypospadias
*Increased risk of endometrial 
cancer, especially at doses greater 
than 2000 mg and high (more than 7) 
number of cycles
Metformin *Usually used in young girls and adolescents with 
PCOS as first-line monotherapy or in combination 
with anti-androgen medications and OCPs
*Improve hyperandrogenemia and symptoms of 
androgen excess
*Recovery ovary function with normal menses
*Assist in weight reduction
*Reduce in metabolic parameters of insulin 
resistance
*Promoting ovulation is still 
controversial
*Maybe increase IR after a 2-year 
period of intervention
Oral conceptions *Contain estrogen (almost exclusively 
ethinylestradiol) and a progestin
*Decrease androgens and block the effect of 
androgens by inhibiting of ovarian androgen 
production and by increasing SHBG
*Advantageously combined with an anti-androgen 
to attain a better effect when treating hirsutism  
and alopecia
*Progestins, such as chlormadinone 
and drospirenone, may increase 
venous thrombosis events and may 
be contraindicated in severe obesity 
patients.
*Little effect in blocking mild to 
moderate hirsutism or alopecia with 
OCPs only
Anti-androgens *Competitive antagonism of the androgen receptor 
(spironolactone (SPA), cyproterone acetate, 
flutamide) or suppression of 5α-reductase (5αR, 
such as finasteride) to prevent the conversion of 
5α-dihydrotestosterone into free testosterone
*Suppress the effects of androgen in the hair follicle 
or in the pilosebaceous unit
*SPA may induce hyperkalemia, 
breast discomfort, dry skin, gastritis, 
headaches and dizziness
*Intermenstrual spotting may occur if 
the women taking SPA as monotherapy
*SPA has the potential for 
teratogenicity
Steroids *Physiologic doses of prednisolone or 
dexamethasone can reduce androgen output  
directly
*Less effective for the treatment of 
hirsutism
Statins *Lipid-lowering agents with multiple actions to 
improve dyslipidemia
*Combined with an OCP can improve hirsutism
*Statins alone do not improve 
hirsutism, menstruation, or BMI
Table 3. Current medical agents and limitations for PCOS.
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improved insulin sensitivity [57]. Metformin could reduce body weight, improve menstrual 
pattern, and decrease LH, oestradiol levels, androgens, and AMH levels [57]. Table 3 lists the 
medical treatment agents and limitations for PCOS [58–67].
Bariatric surgery is used for weight reduction in patients with morbid obesity. One systematic 
review showed that bariatric surgery can improve postoperative conception rates, hirsutism, 
menstrual irregularities, and hormonal abnormalities in women with PCOS [68]. Another sys-
tematic review and meta-analysis about bariatric surgery demonstrated that the incidence of 
PCOS preoperatively was 45.6%, which significantly decreased to 6.8 and 7.1% at the 1 year 
follow-up and study endpoint, respectively [69]. Moreover, it also demonstrated nearly a 50% 
improvement in menstrual irregularity and a 30% improvement in hirsutism [69]. There is 
still a lack of evidence for the improvement in fertility after bariatric surgery [68, 69]. One 
report revealed the tendency of increasing infant mortality in the bariatric group and bariatric 
surgery may have its own unique risk-benefit ratio with regards to pregnancy results [70].
5. Traditional Chinese medicine
Traditional Chinese medicine formulas and herbs have been used to manage the health prob-
lems of women for hundreds of years. Classically, Chinese medicine prescription is com-
posed of many herbs to treat a specific disease. According to the principles of TCM syndrome 
patterns for PCOS, one study showed that Shen deficiency with blood-stasis syndrome was 
the most frequent pattern noted in these patients, followed by Pi-deficiency with phlegm-
dampness syndrome, Pi-Shenyang-deficiency syndrome, and Shen-yin deficiency syndrome 
[71]. Another study demonstrated that TCM syndrome patterns presented in patients with 
PCOS were mostly amalgamative, of which Shen deficiency and Gan stagnancy are the basic 
syndromes [72]. One earlier study revealed that elevated levels of testosterone correlated 
more with the TCM syndrome pattern of Shen-Yi deficiency compared to other patterns [73]. 
Interestingly, there is one study that describes the correlation between TCM syndrome pat-
terns of PCOS and ovulation induction effects [74]. The effects of clomiphene on patients with 
phlegm-dampness accumulation syndrome and Shen-yin deficiency syndrome were poorer 
than in patients with Shen-yang deficiency syndrome and Gan-stagnancy transformed heat 
syndrome, which suggested the degree of reproduction endocrine dysfunction or the metabo-
lism disturbance of the former two syndrome patterns were more severe than the latter two 
syndrome patterns [74].
5.1. Chinese herbal formulas for PCOS
5.1.1. Jia-Wei-Xiao-Yao-San
Jia-Wei-Xiao-Yao-San, also called Dan-Zhi-Xiao-Yao-San, consists of Moutan Radicis Cortex, 
Radix Paeoniae Rubra, Bupleuri Radix, Angelicae Sinensis Radix, Poria, Glycyrrhizae Radix, 
Atractylodes Ovatae Rhizoma, Zingiberis Rhizoma Recens, and Menthae Herba. According 
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to the principles of TCM, Jia-Wei-Xiao-Yao-San disperses stagnated liver qi for relief of qi 
stagnation and suppresses heat and nourishes the blood. One study showed that a danzhi 
xiaoyao pill could improve ovulation rates and pregnancy rates in anovulation infertility 
patients with PCOS complicated by IR [75]. It was also reported as the most frequently pre-
scribed formula for patients with PCOS in north Taiwan [76].
5.1.2. Wen-Jing-Tang
Wen-Jing-Tang consists of Cinnamomi Ramulus, Evodiae Fructus, Ligustici Rhizoma, Angelicae 
sinensis Radix, Paeoniae Radix, Ginseng Radix, Glycyrrhizae Radix, Zingiberis Rhizoma Recens, 
Moutan Radicis Cortex, Ophiopogonis Tuber, Pinelliae Tuber, and Asini Corii Gelatinum. According 
to the principles of TCM, Wen-Jing-Tang would promote blood circulation to dispel blood 
stasis, dispels cold by warming the meridians, benefits qi, and nourishes the blood. One study 
showed that Wen-Jing-Tang was effective in regulating endocrine conditions in the treatment 
of ovulation disorders in patients with PCOS [77]. It suggested that Wen-Jing-Tang is ade-
quate for the clinical management of PCOS in women with various constitutions (as deter-
mined by the matching theory of eight-principle pattern identification) [77].
5.1.3. Cang-Fu-Dao-Tan-Wan
Cang-Fu-Dao-Tan-Wan consists of Atractylodes Lanceae Rhizoma, Cyperi Rhizoma, Pinelliae 
Rhizoma, Citri Reticulata Pericarpium, Poria, Citrus aurantium L., Glycyrrhiza Radix, and Arisaema 
heterophyllum Bl. According to principles of TCM, Cang-Fu-Dao-Tan-Wan resolves phlegm 
and dissipates masses, eliminates dampness, and relieves depression. One study evaluated 
the efficacy of a modified Cangfu Daotan pill combined with clomiphene in patients with 
PCOS. The results showed that the modified Cangfu Daotan pill could improve symptoms, 
increase ovarian artery blood flow, and lower FSH and LH [78]. Another study evaluated a 
modified Cangfu Daotan Decoction (MCDD) on endometrial receptivity in infertility patients 
with PCOS [79]. MCDD could increase pregnancy rates with improving insulin resistance, 
endometrial blood flow, endometrial receptivity, and increasing the uncoupling protein 
(UCP2) expression [79]. UCP2 expression, negatively regulating the hypersensitivity of insu-
lin, has been reported to be significantly higher in early stage follicles of ovary tissue in PCOS 
patients [80], but the mechanism and function in the endometrium remains unknown.
5.2. Single Chinese herbs for PCOS
5.2.1. Cyperi Rhizoma
Cyperi Rhizoma, also called Xiang Fu in Chinese, originates from dried roots of Cyperus rotun-
dus L. According to the principles of TCM, it can disperse and rectify depressed liver-energy, 
regulating menstruation, and arresting pain. Cyperi Rhizoma was also reported as the most 
frequently prescribed single herb in north Taiwan for patients with PCOS [76]. It may have 
potential for PCOS treatment due to its pharmacological benefits resulting in anti-androgenic, 
anti-diabetic, anti-lipidemic, anti-obesity, and weight-control effects in obese patients accord-
ing to the present research results [81, 82].
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5.2.2. Radix Salvia Miltiorrhiza
Radix Salvia Miltiorrhiza, also called Dan Shen in Chinese, originates from dried roots of Salvia 
miltiorrhiza Bunge. According to the principles of TCM, Dan Shen can promote blood flow to 
regulate menstruation, cool blood, and dispel blood stasis. Tanshinone, the main ingredient 
of Salvia miltiorrhiza Bunge [83], may decrease the level of androgen and improve the index of 
lipid metabolism, such as lower total cholesterol and TG, and increase HDL levels, in patients 
with PCOS [84]. Some animal studies have shown that Cryptotanshinone can reverse repro-
ductive disturbances by decreasing the levels of SHBG, testosterone, estradiol, and LH, as 
well as the LH/FSH ratio, and can improve metabolic disturbances, such as abnormal levels of 
LDL-C and FINS by dehydroepiandrosterone (DHEA)-induced PCOS [84, 85].
5.2.3. Coptidis Rhizoma
Coptidis Rhizoma, also called Huang Lian in Chinese, originates from dried roots of Coptis deltoidea 
C.y.Cheng et Hsiao. or Coptis chinensis Franch. or Coptis teeta Wall. According to the principles of 
TCM, Coptidis Rhizoma can clear heat, eliminate dampness, spill fire, and induce detoxification. 
The isoquinoline alkaloid and the major constituent, berberine, are derived from this herb [86]. A 
previous randomized study showed that berberine, compared with metformin, could decrease 
BMI, lipid parameters, and total FSH requirements, and increase the live birth rate with fewer 
gastrointestinal adverse events in patients with PCOS undergoing IVF treatment [87]. Another 
earlier randomized study demonstrated that berberine, compared with metformin, could reduce 
total cholesterol, TG, LDL-C, WC, and waist-to-hip ratio, as well as elevate HDL-C and SHBG 
in patients with PCOS [88]. Coptidis Rhizoma may have potential for the management of PCOS.
6. Acupuncture and moxibustion
As with TCM formulas and single Chinese herbal therapy, acupuncture and moxibus-
tion have also been used to treat clinical manifestations of PCOS for hundreds of years. 
Traditionally, acupuncture and moxibustion were performed by inserting needles into 
or burning moxa sticks upon specific points (acupoints) on the meridians of the body 
surface. Acupuncture and moxibustion work by regulating energy flow, also called Qi 
in Chinese, over the meridians. Newer therapeutic methods include electro-acupuncture 
(EA), laser-acupuncture, burning moxa granules on the top of the needle, points pasting, 
and far-infrared moxibustion.
Clinical effects of acupuncture are mediated by activation of somatic afferent nerves innervating 
the skin and muscle, which, via modulation of the activity in the somatic and autonomic nervous 
system, may regulate metabolic and endocrine functions in patients with PCOS [89]. One analy-
sis showed that the acupoints of Sanyinjiao (SP 6), Guanyuan (CV 4), Zigong (EX-CA 1), Zhongji 
(CV 3), and Qihai (CV 6) are most frequently used in the clinical management of acupuncture 
for patients with PCOS [90]. This report also demonstrated the meridians of the main acupoints 
are the conception vessel, stomach meridian of the foot-yangming, and the spleen meridian of 
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foot-taiyin. The main acupoints are distributed in the lower limbs, lower abdomen, and back 
[90]. In the special points, usage of front-mu points, five-shu points, and back-shu points are 
more frequently used and the prescription is usually an average of five to seven acupoints [90].
One prospective clinical study investigated responses to 5 weeks of EA in overweight-obese 
women with PCOS [91]. The results showed that HbA1c levels and circulating and adipose tissue 
androgens were significantly decreased, together with modulation of vagal activity and adipose 
tissue sympathetic activity [91]. A systematic review and meta-analysis demonstrated that man-
ual acupuncture (MA) or EA can improve clinical pregnancy rates and ongoing pregnancy rates, 
and lower the risk of ovarian hyperstimulation syndrome (OHSS) in women with PCOS under-
going in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) [92]. Another RCT 
revealed that serum androgens decreased and menstrual frequency increased after 16 weeks of 
EA intervention, while the acne improved after the 16-week follow-up in the EA group com-
pared to the exercise group [93]. The other RCT showed that serum levels of AMH were signifi-
cantly decreased in the EA group compare with the change in the exercise group after 16 weeks 
of intervention, but there was no difference in the exercise group and the no intervention group 
at 32 weeks follow-up [94]. An earlier RCT found that abdominal acupuncture for obese patients 
with PCOS can reduce BMI and WHR and increase menstrual frequency more effectively, and 
with fewer adverse effects, than metformin after a 6-month trial [95].
True (EA group) and sham (Park sham device group) acupuncture (EA V.S. Park sham device) 
may have similar effects on mean ovulation rates and reproductive endocrine changes, but 
the true acupuncture group could show lower fasting insulin and free testosterone levels after 
8 weeks of intervention [96]. Another RCT showed that the utilization of acupuncture with 
or without clomiphene, compared with control acupuncture and placebo, did not increase 
live births in patients with PCOS [97]. A recent systematic review and meta-analysis demon-
strated that acupuncture may be more likely to improve ovulation rates and menstruation 
frequency than no acupuncture in patients with PCOS [98]. This report also noted that acu-
puncture could be as an adjunct to medication with regard to LH, LH/FSH ratio, testosterone, 
fasting insulin, and pregnancy rates [98]. Another study revealed that there were very few 
RCTs have been reported and there was deficient evidence to support the use of acupuncture 
for management of ovulation problems in patients with PCOS [99].
7. Conclusions
Traditional Chinese medicine formulas or single herbs have been shown to be effective in 
many clinical or animal studies to restore regular menstruation, relieve symptoms, and 
improve ovulation dysfunction in patients with PCOS. Acupuncture, both EA and MA, have 
the potential to change the local ovarian hyperandrogenic environment and improve repro-
ductive and endocrine metabolic disorders in PCOS. Thus, better outcomes can be achieved 
through complementary therapy with TCM for PCOS, expediting and boosting treatment 
efficacy, and ultimately leading to decreased medical costs. However, more clear, effective, 
and safe evidence for the use of TCM management for PCOS is needed in the future.
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